Shares of Knight Therapeutics (GUD) were revisited by a Wall Street analyst today. Analyst David Novak from Raymond James reiterated a Buy rating, with a C$10.25 price target.
According to TipRanks.com, Novak is ranked #2546 out of 5224 analysts.
Read also: Tilray (TLRY) Ramping up Cannabis Supply in Canada with Acquisition of Natura Naturals Holdings
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Knight Therapeutics with a C$9.13 average price target.
The company has a one-year high of C$8.81 and a one-year low of C$7.48. Currently, Knight Therapeutics has an average volume of 239.3K.
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite.
The company’s shares closed on Friday at C$7.74.
